Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transition to GP2013 versus continued originator rituximab in active rheumatoid arthritis
2012-003876-38Phase 3Completed
- Sponsor
- Hexal AG
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by Hexal AG. Primary endpoints: Safety variables and Immunogenicity. Started Apr 2015; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-003876-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003876-38.